Tyrosine kinase inhibitors (TKIs) have dramatically changed the outcome of patients with EGFR‐positive non‐small‐cell lung cancer (NSCLC) [1, 2, 3, 4]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.